PF-Atlas › Clinical Trials › NCT02605590

Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers

AIR DNase · Phase 1

Registry ID

NCT02605590

Phase

Phase 1

Status

Completed

Drug / intervention

AIR DNase

Sponsor

Protalix

Start

2015-12

About this trial

AIR DNase is evaluated in NCT02605590, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Protalix. Current status: Completed.

View NCT02605590 on ClinicalTrials.gov →

Explore related

All AIR DNase trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02605590 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.